Adjuvanted Hepatitis B vaccine (Recombinant) (Dynavax)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAdjuvanted Hepatitis B vaccine (Recombinant) (Dynavax)
Drug Alias Name้‡็ป„ไน™่‚ไฝๅ‰‚็–ซ่‹—-DynavaxHepatitis B Vaccine (Recombinant), Adjuvanted้‡็ป„ไน™ๅž‹่‚็‚Žไฝๅ‰‚็–ซ่‹—-DynavaxHBV-ISS preventative vaccineHBV vaccine preventative +[13]ย 
ClassificationVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulantsToll like receptor 9 agonists
TargetsToll like receptor 9
Therapy Area/IndicationsKidney Failure, ChronicHepatitisHepatitis B, Chronic +[4]ย 
Global Approved IndicationsHepatitis B
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/11/09
Country/TerritoryCanadaUnited StatesGermany +[4]ย 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesDynavax Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesDynavax GmbhDynavax Technologies CorpUniversity Of Maryland, Baltimore +[4]ย 
Inactive CompaniesBaylor Research Institute LlcNational Heart, Lung, And Blood Institute (Nhlbi)
Active IndicationsHepatitis B, ChronicHepatitis B
Inactive IndicationsKidney Failure, ChronicHepatitis

Other Information

ATC CodeJ07BC
Related LinksN/A